The Center for Biosimilars® recaps the top news for the week of October 29, 2018.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 29.
Number 5: Given the high burden of cancer in the senior population, and given the increasingly high cost of cancer care, there is a growing interest in value-based oncology care payment models, particularly within CMS.
Number 4: While real-world data have been reassuring about the feasibility of switching patients with inflammatory diseases from reference infliximab to biosimilar CT-P13, some ambiguous data in patients with inflammatory bowel disease have raised questions among clinicians about switching in the indications of Crohn disease and ulcerative colitis.
Number 3: Four people have been indicted for allegedly stealing trade secrets over the course of 5 years related to the biopharmaceutical dornase alfa and some of Roche’s top-selling cancer drugs: rituximab, trastuzumab, and bevacizumab.
Number 2: In recent years, spending on specialty drugs, including spending on a proliferation of orphan drugs that treat rare diseases, has raised concerns about sustainability of the healthcare system.
Number 1: This week the FDA approved 2 biosimilars, Sandoz’s biosimilar adalimumab, and Coherus’ biosimilar pegfilgrastim.
Finally, last week, our e-newsletter asked if provider concern with the immunogenicity of biosimilars is appropriate.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.